Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9005309 | 0.95 | CA4 (0.41) | CA4DGAT1CYP2D6CA2CA12 | |
| Lithium Ion SCHEMBL223524 | 0.95 | CA4 (0.41) | CA4DGAT1CYP2D6CA2CA12 | |
| SCHEMBL241533 | 0.82 | DGAT1 (0.46) | DGAT1CYP2D6CA2CA12CA14 | |
| Potassium Ion SCHEMBL28727566 | 0.80 | CA4 (0.36) | CA4 | |
| Methyl Alcohol SCHEMBL27995686 | 0.79 | DGAT1 (0.44) | DGAT1CYP2D6CA2CA12CA14 | |
| SCHEMBL28315778 | 0.77 | CA4 (0.42) | CA4CA2HDAC3HDAC1HDAC2 | |
| SCHEMBL28727603 | 0.77 | CA4 (0.38) | CA4 | |
| SCHEMBL2648388 | 0.77 | DGAT1 (0.42) | DGAT1CYP2D6CA2CA12CA14 | |
| SCHEMBL28316203 | 0.77 | DGAT1 (0.42) | DGAT1CYP2D6CA2CA12CA14 | |
| SCHEMBL19459343 | 0.76 | DGAT1 (0.38) | DGAT1CYP2D6CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773335-A | Preparation method of 6-halo-4-hydroxy-1, 5-naphthyridine-3-formic acid and ester thereof | 内蒙古京东药业有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-114315746-A | 3, 6-bis (dinitromethyl) -1,2,4, 5-tetrazine and synthetic method thereof | 南京理工大学 | 2022-04-12 | — | — | CN | claimed |
| CN-109867679-B | Preparation method of piricaconide hydrochloride intermediate | 杭州瀚康生物医药科技有限公司 | 2021-11-30 | — | — | CN | claimed |
| EP-4724441-A1 | ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF | Revir Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4695242-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024251212-A1 | ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF | REVIR THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024251211-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR MODULATING SPLICING OF MSH3 | REVIR THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024212907-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | META PHARMACEUTICALS (HK) LIMITED (CN) | 2024-10-17 | — | — | WO | disclosed |
| CN-111032034-B | Spiro compounds and methods of making and using the same | H.隆德贝克有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-114315746-A | 3, 6-bis (dinitromethyl) -1,2,4, 5-tetrazine and synthetic method thereof | 南京理工大学 | 2022-04-12 | — | — | CN | disclosed |
| EP-3675848-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2022-03-23 | — | — | EP | disclosed |
| US-5216174-A | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT CO. (US) | 1993-06-01 | — | — | US | disclosed |
| US-5149837-A | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1992-09-22 | — | — | US | disclosed |
| US-5124482-A | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1992-06-23 | — | — | US | disclosed |
| US-5097045-A | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1992-03-17 | — | — | US | disclosed |
| US-5003080-A | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1991-03-26 | — | — | US | disclosed |
| EP-0330172-A2 | Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1989-08-30 | — | — | EP | disclosed |
| US-4375433-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1983-03-01 | — | — | US | disclosed |
| US-4252722-A | CHEMICAL INTERMEDIATE | MERCK & CO., INC. (US) | 1981-02-24 | — | — | US | disclosed |
| EP-0010312-A2 | Process for the preparation of 6-hydroxymethyl-2-(beta-aminoethylthio)-1-carbadethiapen-2-em-3-carboxylic acid and intermediates useful in this process | MERCK & CO. INC. (US) | 1980-04-30 | — | — | EP | disclosed |